Know Cancer

or
forgot password

Combination of Continuous Low Doses of Vinorelbine, Cyclophosphamide and Interferon Alpha 2b for Antiangiogenic/Antivascular Effect in Adult Advanced Neoplasm


Phase 1
18 Years
N/A
Not Enrolling
Both
Advanced Neoplasm

Thank you

Trial Information

Combination of Continuous Low Doses of Vinorelbine, Cyclophosphamide and Interferon Alpha 2b for Antiangiogenic/Antivascular Effect in Adult Advanced Neoplasm


Inclusion Criteria:



- patients aged from 18 and older,

- with metastatic or advanced solid tumor who received all standard treatments,

- who ended their chemotherapy or radiotherapy treatment within 4 weeks (6 weeks for
mitocyne)prior entry in the study.

- All patients are included after being given written informed consent.

Exclusion Criteria:

- patients with stable disease,

- history or presence of another cancer,

- contraindication to administer the treatment,

- contraindication to perform MRI,

- pregnancy or breast feeding.

Type of Study:

Interventional

Study Design:

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Estimation of the toxicity of the combination of continuous low doses of Vinorelbine, Cyclophosphamide and Interferon alpha 2b.

Outcome Time Frame:

6 weeks

Safety Issue:

Yes

Principal Investigator

Anthony GONCALVES, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Institut Paoli-Calmettes

Authority:

France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)

Study ID:

METRO1/IPC2005-001

NCT ID:

NCT00908869

Start Date:

May 2006

Completion Date:

May 2011

Related Keywords:

  • Advanced Neoplasm
  • advanced neoplasm
  • adult advanced neoplasm
  • Neoplasms

Name

Location